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Objectives: To investigate early vertical growth patterns and factors associated with poor growth in a
modern inception cohort of UK children with juvenile idiopathic arthritis (JIA) using data from the
Childhood Arthritis Prospective Study (CAPS).
Methods: A study period of 3 years was chosen. Children included in this analysis had a physician
diagnosis of JIA and had height measurements available at both baseline and at 3-years of follow-up.
Height is presented as z-scores calculated using World Health Organisation growth standards for age and
gender. Growth over the 3-year period was assessed using change in z-score and height velocity.
Univariable and multivariable linear regressions were used to identify factors associated with height
z-score at baseline and change of height z-score at 3 years.
Results: 568 patients were included; 65% female, median baseline age 7.4 years [interquartile range (IQR)
3.6, 11.2], median symptom duration at presentation 5.5 months [IQR 3.1, 11.6]. Height z-score decreased
significantly from baseline to 3 years (p ≤ 0.0001); baseline median height z-score was −0.02 (IQR −0.71,
0.61), decreasing to −0.47 (IQR −1.12, 0.24) at 3 years. Growth restriction, defined as change of height
z-score ≤−0.5, was observed in 39% of patients. At 3 years, higher baseline height z-score was the
strongest predictor for a negative change in height z-score [−0.3 per unit of baseline height z-score
(95% CI: −0.36, −0.24), p o 0.0001].HS Journals, Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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F. McErlane et al. / Seminars in Arthritis and Rheumatism ] (2017) ]]]–]]]2Conclusions: Although overall height at 3 years after initial presentation to rheumatology is within the
population norm, as a cohort, children with JIA experience a reduction of growth in height over the first
3 years of disease. Late presentation to paediatric rheumatology services is associated with lower height
at presentation. However, patients with the lowest height z scores at presentation were also the most
likely to see an improvement at 3 years. The impact of JIA on growth patterns is important to children
and families and this study provides useful new data to support informed clinical care.
& 2017 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Key messages
• The study identified that growth restriction in JIA can occur
early after disease onset.
• Growth restriction was observed in 39% of patients.
• Decrease in height z-score occurred across all JIA subtypes and
was greatest in sJIA and PsJIA.Introduction
Inflammatory arthritis is one of the most common chronic
inflammatory illnesses in childhood. It has been estimated that
approximately 1:10,000 children will develop an inflammatory
arthritis each year [1] with the majority subsequently diagnosed
with juvenile idiopathic arthritis (JIA).
Growth disturbance is an important complication of JIA, with
significant implications for both physical and psychosocial health.
Although initially reversible, long-standing growth impairment
results in irreversible short stature and altered adult body compo-
sition. It is a significant concern for the families of young children
with JIA and an additional challenge for older children and
adolescents coping with the impact of chronic illness [2].
Understanding the prevalence of short stature in JIA has tradi-
tionally been challenging, with estimates ranging from 1% to 17%
[3]. Previous studies have defined juvenile arthritis according to
different classification criteria and have included different sub-
types of disease [4–6], using retrospective or cross-sectional study
designs with variable lengths of follow-up, even within the same
study. This risks the introduction of selection bias towards those
children with the most severe disease requiring long-term
rheumatological follow-up.
In recent years, biologic therapies such as etanercept and
tocilizumab have been associated with improvements in vertical
growth [7]. As a consequence, studies predating the widespread
use of methotrexate or biologics may no longer be relevant to
current populations of children and young people with JIA. More
recent studies suggest that growth impairment persists in around
10% patients [8], despite intensification of treatment regimens and
the advent of biologic therapies [7,9–11].
The reasons for poor growth in JIA are multifactorial and may
relate to the degree of systemic inflammation, corticosteroid use [12]
or nutrition [13]; appetite may be impaired as a consequence of
chronic inflammatory disease or as a side-effect of drugs with
gastrointestinal toxicity such as methotrexate (MTX). Protein/energy
malnutrition is thought to occur in children with JIA [14] and has
been found to correlate with disease severity [15]. The extent of
growth failure may vary with the ILAR subtype and is well described
in children with polyarticular and systemic JIA [12,16,17]. In 2011, a
review of 95 patients with oligoarticular JIA identified growth
restriction in 36% patients [18]. Systemic corticosteroid use in JIA
has been associated with a reduction in final adult height [12,19,20].
There is evidence that glucocorticoids interfere with the production
or action of growth hormone and its mediators at different levels of
the GH-insulin-like growth factor I axis [21].
The aim of this analysis was to investigate early growth
patterns and factors associated with poor growth in a modern
inception cohort of UK children and young people (CYP) with JIAover the first 3-years following diagnosis, using data from the
Childhood Arthritis Prospective Study (CAPS).Materials and methods
Study population
Children in this analysis were participants in CAPS, an ongoing
inception cohort study launched in 2001 [22]. Children aged o16
years presenting to one of 7 paediatric and adolescent rheumatol-
ogy referral centres across UK with a new diagnosis of inflamma-
tory arthritis lasting for at least 2 weeks in at least one joint, are
eligible to participate. The study was approved by the UK North-
west Multicentre Research Ethics Committee.
Baseline data collection
Data are obtained through medical case note review, patient
questionnaires and interview. Data collected include active and limited
joint counts, 100-mm physician's global assessment (PGA) visual
analogue scale (VAS), 100-mmpain VAS, and a 100-mmparent general
evaluation (PGE) VAS, the child health assessment questionnaire
(CHAQ). The physician assigns an International League Against Rheu-
matism (ILAR) subtype where appropriate. Additional demographic
and health information data are provided by the families alongside
completion of patient reported outcome questionnaires. Follow-up
data are collected annually for the first 5 years following presentation
and include all of the same information as collected at baseline. When
children are discharged from paediatric rheumatology care, a study
nurse will continue to collect follow-up data for a further 2 years.
Measurement of height
The height in centimetres and weight in kilograms of all children
are measured routinely during hospital clinic appointments as per
local hospital protocol and recorded in the hospital case notes. For
the purpose of this study, height measurements from the first
paediatric rheumatology visit constituted baseline. Study nurses were
advised to record the measurements which most closely corre-
sponded to the study follow-up intervals, along with the date of
measurement. Body mass index (BMI) was calculated subsequently.
Analysis
A study period of 3 years was chosen to enable capture of
definitive treatment data and early growth patterns. Children were
included in this analysis if they had a diagnosis of JIA and had
height measurements available at both baseline and at 3-years (±
3 months) of follow-up. Height and BMI are presented as z-scores,
a standard score that indicates how many standard deviations an
observation differs from the age and gender adjusted population
median. Population data for the determination of z-scores were
obtained from the World Health Organisation (WHO) website
(http://www.who.int/childgrowth/en/) and the following calcula-
tion per child and height/BMI measurement was used: [observed
F. McErlane et al. / Seminars in Arthritis and Rheumatism ] (2017) ]]]–]]] 3value-median value of reference population]/standard deviation (sd)
of reference population].
Height velocity was calculated using the following formula:
ΔHeight (cm)/Time (years)
Growth over the 3 years period was assessed using change in z-
score and height velocity. As height z-score is a standardised
measure, children would be expected to remain at the same height
z-score over time, therefore any negative change in the z-score is
considered a poor growth rate. We defined poor growth as a change
of height z-score ≤−0.5 and severe growth restriction as height z-
score change ≤−1 as previously described [7,18]. Short stature was
defined as a height z-score o−2 [18,19]. Data are presented for the
whole cohort and by ILAR category. As ILAR categories can change
over time, we used the most recent ILAR category to allow children
to “settle” into a category. Median annual height velocity over the
3-year period was plotted for each child and compared with WHO
median height velocity standards. BMI classification was defined
using the Extended International (IOTF) Body Mass Index Cut-Offs
for Thinness, Overweight and Obesity in Children (http://www.iaso.
org/resources/reports/newchildcutoffs).
Differences between baseline and 3 year height z-scores were
compared using the Student’s paired t test. Univariable and multi-
variable linear regressions were performed to identify factors
associated with (1) height z-score at baseline and (2) with the
change of height z-score at 3 years. Co-variates in both models
included baseline demographics [age at baseline, gender], patient
reported outcome measures (PROMS) [CHAQ and pain VAS] and
symptom duration atfirst presentation. In addition, model 1 included
JADAS71 at baseline and the model 2 included change in JADAS71
from baseline to 3 years and treatment over the first 3 years [total
time on oral/iv steroids in weeks, total number of intra-articular
corticosteroid injections (IACI), DMARDS (yes/no) and biologic
agents (yes/no)]. The results are presented as coefficients with 95%
CIs. Multiple imputation was used to account for missing co-variate
data, with 20 imputation sets generated. Analyses were performed
in Stata version 13.1 (Statacorp 2003, College Station, TX, USA).Results
Up to October 2014, CAPS had registered 1451 patients with JIA.
Of these, 1184 had reached 3 years in the study of which 818
children had completed their 3-year follow-up. 690 of these
children had height and weight recorded at 3 years but 122 had
no height recorded at baseline, leaving 568 children for inclusion
(Fig. 1). Compared to children who had reached 3 years in the
study but did not have available height and weight data at both
time points, those included in the analysis were slightly younger at
presentation, had longer disease duration at baseline and were
more likely to have a polyarticular disease course (Table 1).
Treatment
Over the three years following first presentation, 359 (63%)
children received treatment with DMARDS, primarily methotrex-
ate, 121 (21%) also received biologic therapy, 254 (44%) received
systemic steroids over a total median cumulative time of 4.1 weeks
(IQR 0.4, 22) and 448 (78%) received IACIs with median total
number of injections of 4 (IQR 2, 8)/patient (Table 2).
Anthropomorphic data
At presentation, median height z-score was −0.02 (IQR −0.71,
0.61) (Table 3). Twenty patients (4%) were classified as havingshort stature at baseline (Fig. 2). Median height z-score at 3 years
decreased to −0.47 (IQR −1.12, 0.24), an overall median change of
−0.31 (−0.80, 0.10). The 3-year median height z-score was signifi-
cantly different from baseline height z-score (p ≤ 0.0001). Growth
restriction was observed in 39% of patients (22% moderate and 17%
severe growth restriction), and 42 (7%) had short stature after
3 years. Median height velocity was 5 cm/year (IQR 4, 6.2) with
more than 70% of patients showing lower height velocity against
age and gender matched reference population (Fig. 3). Decrease in
height z-score occurred across all JIA subtypes and was greatest in
systemic arthritis (sJIA) and psoriatic arthritis (PsA) with a change
of −0.50 (IQR −0.97, −0.29) and −0.40 (IQR −1.02, 0.07), respec-
tively. At baseline, median BMI z-score was slightly above the
reference population [0.36 (IQR −0.35, 1.3)] (Supplementary Table).
Overall, there was no appreciable change in median BMI z-score at
3 years [−0.11 (IQR −0.52, 0.39)], but there was an increase in
children with sJIA [þ0.33 (IQR −0.52, 0.66)] and moderate
decrease in patients with extended oligoarthritis [−0.26
(IQR −0.65, 0.27)] and ERA [−0.32 (IQR −0.58, 0.04)]. One hundred
and eighteen (23%) were overweight, obese or morbidly obese at
first presentation and a similar proportion [123 (22%)] at year 3
(Fig. 4).
Factors associated with height z-score and height z-score changes
In multivariable analysis at baseline, higher CHAQ score, longer
symptom duration and lower BMI z-score were significantly
associated with lower height z-scores. Although higher JADAS-71
was significantly associated with lower height at baseline in the
univariate analysis, no association was found in the multivariate
model.
At 3 years, baseline height z-score was the strongest predictor
for improved growth. For every unit decrease in baseline height z-
score, a 0.3 unit increase in height z-score from baseline to 3 years
was predicted [−0.3 per unit z-score (95% CI: −0.36, −0.24), p o
0.0001]. In addition, total time on oral or intravenous steroids
during the 3-year period was significantly associated with
decrease in height z-score from baseline to 3 years (Table 4).Discussion
This is one of the largest longitudinal studies of vertical growth
in all JIA subtypes, particularly focussing on changes to height in
the first 3 years after diagnosis. Although height was within the
normal range at presentation (−0.02), by capturing data system-
atically from first presentation to paediatric rheumatology we
have identified that growth restriction can occur early after disease
onset, both across the entire cohort and within each ILAR subtype.
The simultaneous capture of multiple covariates has allowed us to
explore the impact of disease activity and pharmacological inter-
ventions on growth over this early interval. The dataset was
captured in a modern treatment era, and all children had access
to biologic therapies. Previous analysis of this cohort has not
shown that biologic use has increased significantly over the course
of the study [23].
The greatest decrease in z-score was identified in CYP with sJIA
(−0.5), with 24% experiencing a severe deceleration in vertical
growth. Reduced growth velocity early in the course of sJIA has been
reported previously [9,24,25] and is likely multifactorial. CYP with
sJIA are often systemically unwell at presentation, necessitating
treatment with high dose corticosteroids [24]. The impact of cortico-
steroids on growth velocity and final height is well-described
[12,20,25,26] but it remains unclear whether corticosteroids have
an independent negative effect on growth [21] or simply represent a
marker of disease severity [15,27].
Fig. 1. Patient selection flowchart.
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median duration of 46.6 weeks and it is likely that steroid exposure
contributed to the reduced growth velocity. Total time on oral/IV
corticosteroids over the 3 years was associated with growth
restriction. We observed this association between corticosteroids
and growth even after adjustment for disease activity, disease
duration and DMARDs therapy. A previous study reported signifi-
cant growth restriction in children with no exposure to cortico-
steroids [28], suggesting that growth restriction in sJIA is complex
and may relate directly to the systemic inflammatory process.Table 1
Baseline characteristics of the analysis cohort and a comparison with children excluded
Baseline characteristics Analysis
Age at baseline (median, IQR) 7.4 (3.6
Female (n, %) 372 (65
Ethnicity, Caucasian (n, %) 518 (91)
Symptom duration at first presentation (median, IQR), months 5.5 (3.1
ILAR subtype (n, %)
Systemic arthritis 21 (4)
Persistent oligoarthritis 240 (42
Extended oligoarthritis 54 ( 9)
RF(−)polyarthritis 139 (24
RF(þ)polyarthritis 28 (5)
Enthesitis-related arthritis 30 (5)
Psoriatic arthritis 41 (7)
Undifferentiated arthritis 14 (2)
Active joint counts (median, IQR) 2 (1, 5
Limited joint counts (median, IQR) 1 (1, 3
PGE, mm (median, IQR) 22 (6,
PGA, mm (median, IQR) 28.5 (16,
JADAS 71 9.9 (6, 1
Δ JADAS71 from baseline to 3 years −6.6 (−1
CHAQ (median, IQR) (0–3) 0.75 (0.2
Pain, mm (median, IQR) 30 (9,
All values are median [IQR (interquartile range)] or n (%). Groups were compared usingHigh levels of IL-6 in children with sJIA may further reduce
growth velocity. In 2001, Benedetti et al. [29] identified that
chronic overproduction of IL-6 leads to decreased levels of IGF
binding protein 3, suggesting that IL-6 contributes to the reduced
growth velocity noted in chronic inflammatory states.
41% of CYP with persistent oligoarthritis experienced moderate
growth restriction. Most children were treated with IACI rather
than systemic therapies, with a trend for greater growth restric-
tion among patients who had more IACIs (p ¼ 0.06). Growth
restriction has been reported previously in CYP with JIA treatedfrom the analysis
cohort (N ¼ 568) Excluded cohort (N ¼ 616) p Value
, 11.2) 7.9 (3.5, 12.3) 0.03
) 394 (64) 0.4
545 (89) 0.2
, 11.6) 5.22 (2.5, 10.9) 0.04
54 (9) 0.02
) 296 (48)
36 (6)
) 116 (19)
13 (2)
31 (5)
39 (6)
31 (5)
) 2 (1, 5) 0.2
) 1 (0, 3) 0.04
50) 20.5 (4, 50) 0.5
50) 29 (15, 50) 0.9
7) 10.4 (5.5, 16.8) 0.6
3, −2.7) −6.9 (−13.2, −2.4) 0.4
5, 1.37) 0.625 (0.12, 1.37) 0.09
60) 30 (7, 57) 0.4
non-parametric statistics.
Table 2
Medication use between baseline and 3 years according to ILAR category
Whole
cohort
Systemic
arthritis
Persistent
oligoarthritis
Extended
oligoarthritis
RF(−)
polyarthritis
RF(þ)
polyarthritis ERA PsA Undifferentiated
N 568 21 240 54 139 28 30 42 14
Oral/IV steroids (yes/no) 254 (44) 19 (90) 48 (20) 27 (50) 92 (66) 23 (82) 18 (60) 19 (45) 8 (57)
Median (IQR) weeks
cumulative use/childa
4.1 (0.3, 22.1) 46.6 (23.6, 116.1) 0.7 (0.1, 8.7) 1.8 (0.1, 12.1) 4.6 (0.6, 23.7) 15.5 (0.9, 42.7) 4.6 (0.6, 12.8) 2.9 (0.1, 13) 3 (1, 37)
IACIs (yes/no) 446 (78) 7 (33) 200 (83) 51 (94) 103 (75) 21 (75) 23 (77) 35 (83) 6 (42)
Median (IQR) IACIs/childb 4 (2, 8) 5 (5, 14) 2 (1, 4) 5 (3, 10) 7 (3, 12) 8 (4, 14) 3 (2, 8) 6 (3, 9) 2.5 (1, 10)
DMARD (yes/no) 358 (63) 19 (90) 72 (30) 45 (83) 135 (97) 28 (100) 22 (73) 31 (74) 6 (42)
Biologics (yes/no) 121 (21) 7 (33) 12 (5) 13 (24) 52 (37) 9 (32) 16 (53) 10 (24) 2 (14)
Values are n (%) unless otherwise indicated.
a Includes patients treated with oral/iv steroid.
b Includes patients treated with Intra-articular corticosteroids injection (IACI).
F. McErlane et al. / Seminars in Arthritis and Rheumatism ] (2017) ]]]–]]] 5with IACI [18]. Earlier use of DMARD in CYP requiring repeat IACI
may reduce growth restriction in this group. Our data suggest that
future studies exploring patterns of growth restriction and corre-
lation with steroid prescribing patterns would add important
information.
PsA was also associated with a significant decrease in z-score
(−0.4), with 26% experiencing a severe deceleration in vertical
growth. Low numbers make it difficult to draw firm conclusions
about this subgroup but PsJIA is a multisystem disorder and the
impact of chronic psoriasis on childhood growth is not well
described. The extent of skin involvement was not recorded in
CAPS but may be highly relevant. In particular, IL-6 is highly
expressed in psoriatic skin lesions [30] and is thought to contrib-
ute to reduced growth velocity in chronic inflammation [29].
Delay in presentation to paediatric rheumatology was associ-
ated with lower height at presentation. Previous analysis of this
same dataset identified that children with PsA have the longest
mean time to first presentation to paediatric rheumatology [31],
suggesting that delayed presentation may be an important risk
factor for poor growth in PsA.
Delays in referral to paediatric rheumatology have previously
been identified and may relate to delays in disease recognition
[32–35] or initial referral to specialties other than rheumatology
[31]. It is encouraging that lower height at baseline predicts
improvement in vertical growth over the first 3 years of follow
up. Although this could be explained in part by regression to the
mean, CYP with more pronounced growth restriction at presenta-
tion may demonstrate higher growth velocity with appropriate
treatment [7,9,10,36]. The association between delay from symp-
tom onset to first presentation to paediatric rheumatology and
height z-score change at 3 years was not significant.Table 3
Anthropomorphic data: presented for whole cohort and by ILAR category
N
Height Z score at baseline
(median, IQR)
Height Z score at 3 yea
(median, IQR)
Whole cohort 468 −0.02 (−0.71, 0.61) −0.47 (−1.12, 0.25)
sJIA 21 0.03 (−0.25, 0.40) −0.35 (−0.71, 0.02)
Persistent oligoarthritis 240 0.01 (−0.67, 0.67) −0.50 (−1.01, 0.22)
Extended
oligoarthritiss
54 −0.06 (−0.63, 0.78) −0.58 (−1.25, 0.34)
RF(−)polyarthritis 139 −0.28 (−0.92, 0.46) −0.53 (−1.27, 0.28)
RF(þ)polyarthritis 28 0.18 (−0.53, 0.81) −0.23 (−0.91, 0.54)
ERA 30 0.29 (−0.46, 0.86) −0.27 (−0.73, 0.62)
PSA 42 −0.25 (−0.76, 0.22) −1.02 (−1.34, −0.03)
Height z-score data at baseline and changes after 3 years of follow up. Values are n (%)
a Moderate growth restriction: change in height Z score ≤ −0.5
b Severe growth restriction: change in height Z score ≤−1.A prominent predictor of lower baseline height was the func-
tional disability at first presentation. This is in line with previous
studies where functional class was identified as a factor related to
growth impairment [19,28]. There is also evidence from previous
studies which correlate disease activity and poor growth
[17,18,37]. However, in our analysis disease activity was not
associated with height in multivariable analysis, possibly due to
collinearity between disease activity and disability [38].
An increase in BMI from baseline to 3 years was also associated
with poor growth in height in this cohort. It has been shown
[39,40] that BMI may be abnormal in chronic inflammatory
disorders. A recent study of BMI among children with rheumatic
diseases [39] describes that BMI trajectory reached a peak in the
first 4 months of follow up and then returned to baseline values
while height z-scores trajectories showed continued height defi-
cits. We showed a similar trend with poor vertical growth but no
significant overall change in median BMI z-score during the 3 years
period.
Older age at presentation predicted improvement in vertical
growth. Similarly, a study [7] in 191 etanercept-treated patients
with JIA reported an association between improved growth rates
in patients with ages between 11 and 14 years. This association
may relate to the pubertal growth spurt. Conversely, another study
[28] reported that linear growth observed in sJIA and polyarticular
arthritis during the age of puberty was significantly slower than a
group observed before puberty, suggesting that change in height
during the puberty might be more sensitive to growth-affecting
factors. Unfortunately, in our study, pubertal status data were
unavailable. Although the median age at baseline was 7.4 years,
it is reasonable to assume that a proportion of the study
cohort (particularly the female participants) may have enteredGrowth restriction
rs Δ Height Z score
(median, IQR)
Moderatea
(n, %)
Severeb
(n, %)
Height velocity, cm/year
(median, IQR)
−0.31 (−0.80, 0.10) 223 (39) 99 (17) 5.1 (4, 6.2)
−0.50 (−0.96, −0.29) 11 (52) 5 (24) 4.2 (2, 5.2)
−0.32 (−0.81, 0.08) 99 (41) 42 (18) 5.3 (4.2, 6.3)
−0.31 (−1.06, 0.16) 21 (39) 14 (26) 5.4 (4.4, 6.3)
−0.22 (−0.71, 0.12) 46 (33) 15 (11) 5.1 (4.1, 6)
−0.27 (−1.03, 0.16) 12 (42.9) 8 (29) 4 (2.9, 5.7)
−0.23 (−0.60 ,0.22) 10 (33) 3 (10) 5.1 (3.9, 6)
−0.40 (−1.02, 0.07) 20 (48) 11 (26) 4.4 (3.7, 5.1)
or median (IQR).
Fig. 4. BMI classification at baseline and 3 years. BMI classification was defined
using the Extended International (IOTF) Body Mass Index Cut-Offs for Thinness,
Overweight and Obesity in Children. Abbreviations: BMI ¼ body mass index;
IOTF ¼ International Obesity Task Force.
Fig. 2. Short stature: presented for the whole cohort and by ILAR subtype. †Short
stature: height z score ≤ −2. Abbreviations: sJIA ¼ systemic arthritis; RF ¼
rheumatoid factor; ERA ¼ enthesitis related arthritis; PSA ¼ psoriatic arthritis.
F. McErlane et al. / Seminars in Arthritis and Rheumatism ] (2017) ]]]–]]]6the pubertal growth spurt by three years after the initial
presentation.
Previous publications have shown that control of disease
activity is associated with growth improvement [17,18,36]. How-
ever, in our study, after adjustment for other factors, disease
activity or change in disease activity, measured using the JADAS-
71, was not associated with growth. As our measures of JADAS did
not capture the entirety of disease activity over the follow-up
period, these single measures in time may not accurately capture
disease activity over the follow-up. In addition it is important to
highlight that JADAS does not accurately capture overall disease
activity in all subtypes, in particular sJIA, PsJIA and ERA [41].
Similarly, there is likely to be a strong correlation in many patients
between disease activity and steroid use and disentangling the
role either plays independent of the other is challenging. In some
children, it is possible that using aggressive therapy with systemic
steroids to achieve disease control may have outweighed any
benefit of disease control. This would support the idea that disease
control by aggressive therapeutic approach, but with a minimal
use of systemic steroids, would help to prevent linear growth
restriction in JIA patients [19,25].
The anthropomorphic data captured in this study is real-life
hospital data. Although all seven participating centres collect
height and weight data according to strict hospital protocols,
height measurements were not always taken at the same time ofFig. 3. Average height velocity over 3 years of follow up by age at baseline (male
and female). Median annual height velocity over the 3-year period plotted for each
child and compared against age and gender matched reference population (WHO).
Abbreviation: WHO ¼ World Health Organisation.day or using the same measuring equipment. In addition, it was
not possible to adjust for the impact of joint contractures or limb
length discrepancy on the final height.
Missing anthropomorphic data constitute a further limitation.
Although it is routine to capture height and weight at every
paediatric rheumatology visit, in some cases height and weight
data were either missing or were measured at a time too far from
the 3 year study visit. Anthropomorphic data may be difficult to
obtain in outreach or adult clinic settings and a proportion of
missing data may be due to failure to attend clinical appointments.
A further proportion of children were excluded as they did not
complete 3 years within the study. The reasons for this were
multifactorial and included children who had been discharged for
remission prior to year 3. A further subset of adolescents would
have been transferred to adult rheumatology services. We elected
to exclude these patients rather than make any assumptions about
their height based on earlier measurements. Another possible
limitation is the no inclusion of co-morbidities in our analysis.
Some of these co-morbidities, such as coeliac disease or inflam-
matory bowel disease could impact on the growth. An additional
limitation is that CAPS do not collect pubertal status, markers of
bone age and health. Some of this data has already been collected
within other national cohort studies [42,43], highlighting the
importance of international collaborative studies in rare diseases
such as JIA.
Although there were differences in ILAR distribution between
those included and excluded, the overall differences were
small suggesting these results can, in general, be applied to the
entire cohort. Finally, the study did not have a record of parental
height.
The analysis cohort has a longer disease duration at presenta-
tion than the cohort as a whole (p ¼ 0.04) and a higher proportion
of polyarticular disease patterns (p ¼ 0.02). This suggests that the
analysis cohort may include a higher proportion of children with
more severe disease than routine clinical cohorts.
Identification of growth restriction in the first three years
following presentation is important to children and young people
with JIA. Growth delay has significant potential to impair both
physical and psychosocial health and may impact on longer term
educational and vocational outcomes. This study further highlights
the need for early aggressive treatment regimes in routine clinical
practice. Targeted early treatment pathways are likely to improve
clinical outcomes in children with JIA, and this may include a
reduction in early growth restriction [44].
Table 4
Factors associated with height z-score at baseline and with change in height z-score from baseline to 3 years
Co-variates at baseline
Univariable analysis at baseline,
coefficient (95% CI)
Multivariable analysis at baseline,
coefficient (95% CI)
BMI z-score (per unit) 0.1 (0.05, 0.2)a 0.1 (0.04, 0.2)⁎
Gender (female) 0.14 (−0.05, 0.3) –
JADAS71 (per unit) −0.01 (−0.02,−0.002)a −0.001 (−0.01, 0.01)
CHAQ (per unit) −0.2 (−0.4, −0.1)a −0.2 (−0.4, −0.08)⁎
Pain VAS (mm) −0.002 (−0.005, 0.002) –
Age at baseline (year) −0.005 (−0.03, 0.02) –
Disease duration (per month) −0.01 (−0.01, −0.003)a −0.01 (−0.01, −0.002)⁎
Co-variates
3 years change, univariable analysis
adjusted by medication,b coefficient (95% CI)
3 years change, multivariable analysis adjusted
by medication,b coefficient (95% CI)
Baseline height z-score −0.3 (−0.3, −0.2)a −0.3 (−0.4, −0.2)⁎
BMI z-score change from baseline to 3 years −0.1 (−0.2, −0.05)a −0.1 (−0.15, −0.02)⁎
Gender (female) −0.1 (−0.2, 0.03) –
Disease duration (per month) 0.004 (−0.0001, 0.008)a −0.002 (−0.006, 0.001)
Age at baseline (per year) 0.05 (0.03, 0.07)a 0.05 (0.04, 0.07)⁎
JADAS71 change from baseline to 3 years −0.007 (−0.014, 0.0001)a −0.004 (−0.01, 0.04)
CHAQ (per unit) 0.12 (0.03, 0.2)a 0.07 (−0.04, 0.2)
Pain VAS (mm) 0.002 (−0.001, 0.005) –
Number IACI (per injection) −0.012 (−0.02, 0.0003) −0.012 (−0.02, 0.0004)
Oral/IV steroids (per week) −0.001 (−0.004, 0.002) −0.003 (−0.006, −0.0005)⁎
Ever had DMARD (yes/no) 0.04 (−0.1, 0.2) −0.01 (−0.2, 0.1)
Ever had biologic (yes/no) 0.08 (−0.09, 0.2) 0.01 (−0.15, 0.18)
Univariable and multivariable linear regression for associations with baseline height z-score and with change in height z-score from baseline to 3 years.
a Variables with p ≤ 0.1 in the univariable analysis and therapy were included in the multivariable model.
b Medications were included as co-variates in the statistic model. – Variable not included in the multivariable model.
⁎ p ≤ 0.05.
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This large study has shown that although overall height at
3 years following presentation to rheumatology is within the
population norm, as a cohort, children with JIA do experience an
important loss in vertical growth over the first 3 years of disease.
Continued follow-up of these children into adolescence will
indicate if these early losses in vertical growth can be reversed
prior to reaching final adult height. Future work should include
collection of detailed growth data including pubertal status,
markers of bone age and health and a detailed exploration of
patterns of growth restriction in the different ILAR subtypes.Disclosure statement
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